*Post hoc analysis of the 3-year Toward a Revolution in COPD Health (TORCH) study in patients with moderate or severe COPD (treatment arms: salmeterol 50 mcg, fluticasone propionate 500 mcg, salmeterol/fluticasone propionate 50/500 mcg or placebo, all twice daily). The primary endpoint of the study did not reach statistical significance. Data shown compares patients with >0-1 moderate /severe exacerbations per annum vs. 0 exacerbations per annum. Analysis includes patients on active treatment and placebo.
Seretide (fluticasone propionate/salmeterol xinafoate) is indicated for the symptomatic treatment of patients with COPD, with a FEV1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.5 Seretide prescribing information.
**There was a 2.27 fold (95%CI, 1.1-4.7; p=0.03) increased relative risk of MI 1 to 5 days after exacerbation (defined by prescription of both steroids and antibiotics). There were 20,101 exacerbations and 8 MI events in the 1-5 day post exacerbation period, so the odds of an MI were 1 in 2513 exacerbations. The Health Improvement Network (THIN) database study: 25,857 patients with COPD in 277 practices from THIN database, 25 February 2003 – 24 February 2005